Objective: To evaluate the efficacy and safety of Wenxin Keli for premature beats in structurally normal heart systematically. Methods: Eight databases at home and abroad were searched to collect randomized controlled trials of Wenxin Keli for premature beats without cardiac diseases. The included literatures were systematically evaluated with Cochrane Handbook 5.1 evaluation criteria and tools, and Meta analysis was performed with software RevMan5.3. Results: A total of 13 randomized controlled trials with 1278 subjects were included. The exprimental group used Wenxin Keli alone while the control group used antiarrhythmic medicine. The Meta analysis results showed that the total effective rate(RR=1.06,95％CI [0.97,1.16],P=0.23) and clinical symptom effective rate (RR=1.16,95％CI[0.94, 1.44],P=0.18)of Wenxin Keli on idiopathic premature beats was not significantly different from western medicine group. The subgroup analysis of total effective rate showed that Wenxin Keli had no significant difference with metoprolol (RR=1.04,95％CI[ 0.95,1.15],P=0.41), bisoprolol (RR=1.32,95％CI[0.85,2.05],P=0.22) and propanone(RR=1.07, 95％CI[0.90,1.26],P= 0.44). ECG changes showed that the PR intervals (MD=-12.57,95％CI[-16.15, -8.99],P<0.00001) and QTc intervals (MD=-8.09,95％CI[-15.52, -0.65],P=0.03) in the western medicine group were prolonged significantly more than those of Wenxin Keli. In terms of safety, the incidence of adverse reactions of Wenxin Keli was significantly less than that of western medicine group (RR=0.32,95％CI[0.19, 0.54],P< 0.0001). Conclusion: The efficacy of Wenxin Keli in the treatment of premature beats with structurally normal heart is accurate, and there are no serious adverse reactions. However, because of the low quality of the included papers, which affected the reliability of the conclusions, high-quality clinical research is needed to further demonstrate.